Optimierung einer rekombinanten mikrobiellen Transglutaminase

Büttner, Karin; Marx, Christian; Hertel, T.; Pietzsch, Markus

doi:10.1002/cite.200900104

Cited by 2 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Die Kombination verschiedener Engineering‐Strategien (hier: Substrat‐ und Enzymengineering) ist dabei besonders vielversprechend. Durch Büttner et al ist ein weiteres Beispiel für Enzymengineering gegeben . Die biotechnologische Produktion von Wertstoffen hat in den letzten Jahrzehnten mehrere Phasen durchlaufen.…”

Section: Biotechnologie 1949 Bis Heuteunclassified

90 Years CIT – 90 Years Development in Biotechnology and Bioprocess Engineering

Akermann

Bold

Mehring

et al. 2018

Chemie Ingenieur Technik

View full text Add to dashboard Cite

90 Jahre Chemie Ingenieur Technik (CIT) spiegeln wesentliche Meilensteine der Entwicklung der Biotechnologie und Bioprozesstechnik wider. In diesem Artikel werden einige der wichtigsten Entwicklungen vorgestellt und die Ausbildung von Trends in der Bioverfahrenstechnik nachgezeichnet. Beim Lesen der älteren Artikel lässt sich feststellen, dass einige der aktuellen Forschungsgebiete durchaus nicht ganz so neu sind, sondern vielversprechende Ansätze auch früher schon bearbeitet wurden.

show abstract

Section: Biotechnologie 1949 Bis Heuteunclassified

90 Years CIT – 90 Years Development in Biotechnology and Bioprocess Engineering

Akermann

Bold

Mehring

et al. 2018

Chemie Ingenieur Technik

View full text Add to dashboard Cite

show abstract

“…This molecular diversity holds a considerable potential for the formation of linkages that differ with respect to their potential reactivity to cross-link and thus, contribute to the large range of protein properties [25,26]. The cross-linking of proteins refers to the formation of covalent bonds between polypeptide chains and can be catalyzed, e.g., by enzymes such as microbial transglutaminase that catalyze acyl-transfer reactions between a γ-carboxyamine group of a peptide or protein-bound glutamyl residue and a primary amino group of various substrates including the ε-amino group of lysine or lysyl residues in proteins as shown in Figure 4 [27,28].…”

Section: Protein-based Biocomposites As Drug Delivery Systemsmentioning

confidence: 99%

New Aspects in the Formulation of Drugs Based on Three Case Studies

2016

View full text Add to dashboard Cite

Abstract:The improvement of pharmaceutical dosage forms, such as tablets, towards drug delivery control and cost efficiency is of great importance in formulation technologies. Here, three examples: in situ coating, freeze casting and protein-based biocomposites are presented that address the above mentioned issues and contribute to further developments in formulation technologies. The in situ coating increases the economic efficiency by saving process steps in comparison to a conventional tableting process and provides a crystalline coating for a tailorable drug delivery rate. The freeze casting allows the control over the surface area of a drug delivery system (DDS) by providing different numbers and sizes of pores, which in conjunction with adequate additives offer an efficient instrument for drug delivery control, especially by accelerating the dissolution effect. Protein-based biocomposites are attractive materials for biomedical and pharmaceutical applications that can be applied as a polymeric DDS. They inherently combine degradability in vivo and in vitro, show a good biocompatibility, offer sites of adhesion for cells and may additionally be used to release embedded bioactive molecules. Here, a new approach regarding the incorporation of crystalline active pharmaceutical ingredients (API) into a protein matrix in one process step is presented. All three presented techniques mark decisive progress towards tailor-made drug delivery systems with respect to function, economic efficiency and the generation of additional values.

show abstract

Optimierung einer rekombinanten mikrobiellen Transglutaminase

Cited by 2 publications

References 25 publications

90 Years CIT – 90 Years Development in Biotechnology and Bioprocess Engineering

90 Years CIT – 90 Years Development in Biotechnology and Bioprocess Engineering

New Aspects in the Formulation of Drugs Based on Three Case Studies

Contact Info

Product

Resources

About